Fractured Exhaled Nitric Oxide and Biologic Therapies for Paediatric Asthma
Bronchial asthma is the most frequently diagnosed chronic respiratory disease in children. Treatment approaches should aim to achieve the disease control, reduce limiting symptoms, and improve the quality of life. Routine treatment of patients with asthma relies on assessment of symptoms and spirome...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2023-08-01
|
| Series: | Acta Medica Martiniana |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/acm-2023-0011 |
| _version_ | 1797740359167508480 |
|---|---|
| author | Kunc Peter Fabry Jaroslav Ferenc Peter Hribikova Zuzana Matiscakova Michaela Pecova Renata |
| author_facet | Kunc Peter Fabry Jaroslav Ferenc Peter Hribikova Zuzana Matiscakova Michaela Pecova Renata |
| author_sort | Kunc Peter |
| collection | DOAJ |
| description | Bronchial asthma is the most frequently diagnosed chronic respiratory disease in children. Treatment approaches should aim to achieve the disease control, reduce limiting symptoms, and improve the quality of life. Routine treatment of patients with asthma relies on assessment of symptoms and spirometry results. These diagnostic and therapeutic strategies do not consider the level of inflammation in the airways as a fundamental pathognomonic feature of the disease. The use of biomarkers is increasing in the context of efforts to better understand individual asthma pathways (asthma endotyping), with the potential for personalized treatment with innovative biologics. Elevated levels of exhaled nitric oxide (FENO) represent an indirect marker of T2 inflammation in airways. FENO is one of the few biomarkers that have been applied in routine clinical practice. High levels predict a good therapeutic response to treatment with corticosteroids and selected biologics (Omalizumab, Dupilumab, Mepolizumab, Tezepelumab), or an increased risk of asthma exacerbation. The aim of this review is to evaluate the advantages, disadvantages, and potential applications of this test in relation to new treatment options using biologics for asthma. |
| first_indexed | 2024-03-12T14:11:18Z |
| format | Article |
| id | doaj.art-12be21652d1c45eca3f6bbb98dc28e3b |
| institution | Directory Open Access Journal |
| issn | 1338-4139 |
| language | English |
| last_indexed | 2024-03-12T14:11:18Z |
| publishDate | 2023-08-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Acta Medica Martiniana |
| spelling | doaj.art-12be21652d1c45eca3f6bbb98dc28e3b2023-08-21T06:43:08ZengSciendoActa Medica Martiniana1338-41392023-08-01232748310.2478/acm-2023-0011Fractured Exhaled Nitric Oxide and Biologic Therapies for Paediatric AsthmaKunc Peter0Fabry Jaroslav1Ferenc Peter2Hribikova Zuzana3Matiscakova Michaela4Pecova Renata5Clinic of Children Tuberculosis and Respiratory Diseases, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, and University Hospital Martin, National Institute of Pediatric Tuberculosis and Respiratory Diseases, Dolny Smokovec, Slovak RepublicClinic of Children Tuberculosis and Respiratory Diseases, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, and University Hospital Martin, National Institute of Pediatric Tuberculosis and Respiratory Diseases, Dolny Smokovec, Slovak RepublicClinic of Children Tuberculosis and Respiratory Diseases, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, and University Hospital Martin, National Institute of Pediatric Tuberculosis and Respiratory Diseases, Dolny Smokovec, Slovak RepublicClinic of Children Tuberculosis and Respiratory Diseases, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, and University Hospital Martin, National Institute of Pediatric Tuberculosis and Respiratory Diseases, Dolny Smokovec, Slovak RepublicClinic of Children Tuberculosis and Respiratory Diseases, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, and University Hospital Martin, National Institute of Pediatric Tuberculosis and Respiratory Diseases, Dolny Smokovec, Slovak RepublicClinic of Children Tuberculosis and Respiratory Diseases, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, and University Hospital Martin, National Institute of Pediatric Tuberculosis and Respiratory Diseases, Dolny Smokovec, Slovak RepublicBronchial asthma is the most frequently diagnosed chronic respiratory disease in children. Treatment approaches should aim to achieve the disease control, reduce limiting symptoms, and improve the quality of life. Routine treatment of patients with asthma relies on assessment of symptoms and spirometry results. These diagnostic and therapeutic strategies do not consider the level of inflammation in the airways as a fundamental pathognomonic feature of the disease. The use of biomarkers is increasing in the context of efforts to better understand individual asthma pathways (asthma endotyping), with the potential for personalized treatment with innovative biologics. Elevated levels of exhaled nitric oxide (FENO) represent an indirect marker of T2 inflammation in airways. FENO is one of the few biomarkers that have been applied in routine clinical practice. High levels predict a good therapeutic response to treatment with corticosteroids and selected biologics (Omalizumab, Dupilumab, Mepolizumab, Tezepelumab), or an increased risk of asthma exacerbation. The aim of this review is to evaluate the advantages, disadvantages, and potential applications of this test in relation to new treatment options using biologics for asthma.https://doi.org/10.2478/acm-2023-0011asthmabiologics for asthmabiomarkerschildrenexhaled nitric oxidet2 type inflammation |
| spellingShingle | Kunc Peter Fabry Jaroslav Ferenc Peter Hribikova Zuzana Matiscakova Michaela Pecova Renata Fractured Exhaled Nitric Oxide and Biologic Therapies for Paediatric Asthma Acta Medica Martiniana asthma biologics for asthma biomarkers children exhaled nitric oxide t2 type inflammation |
| title | Fractured Exhaled Nitric Oxide and Biologic Therapies for Paediatric Asthma |
| title_full | Fractured Exhaled Nitric Oxide and Biologic Therapies for Paediatric Asthma |
| title_fullStr | Fractured Exhaled Nitric Oxide and Biologic Therapies for Paediatric Asthma |
| title_full_unstemmed | Fractured Exhaled Nitric Oxide and Biologic Therapies for Paediatric Asthma |
| title_short | Fractured Exhaled Nitric Oxide and Biologic Therapies for Paediatric Asthma |
| title_sort | fractured exhaled nitric oxide and biologic therapies for paediatric asthma |
| topic | asthma biologics for asthma biomarkers children exhaled nitric oxide t2 type inflammation |
| url | https://doi.org/10.2478/acm-2023-0011 |
| work_keys_str_mv | AT kuncpeter fracturedexhalednitricoxideandbiologictherapiesforpaediatricasthma AT fabryjaroslav fracturedexhalednitricoxideandbiologictherapiesforpaediatricasthma AT ferencpeter fracturedexhalednitricoxideandbiologictherapiesforpaediatricasthma AT hribikovazuzana fracturedexhalednitricoxideandbiologictherapiesforpaediatricasthma AT matiscakovamichaela fracturedexhalednitricoxideandbiologictherapiesforpaediatricasthma AT pecovarenata fracturedexhalednitricoxideandbiologictherapiesforpaediatricasthma |